Since the increase in pJNK expression is a principal characteristic in HepG2 cells under lipid overburden[14] and JNK is triggered in the liver tissue of NASH patients[27], the regulation of pJNK might open the therapeutic way for NASH, a chronic liver disease. The gene discussed is MAPK8; the disease is metabolic dysfunction-associated steatohepatitis.